Floatz logo

Inno-206

Anitocabtagene Autoleucel

PETHEMA FoundationPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the Anitocabtagene Autoleucel cohort.

Asset / SponsorPhaseRating
Isatuximab
PETHEMA Foundation
Phase 2CCC
Bortezomib
PETHEMA Foundation
Phase 2CCC
Cyclophosphamide
PETHEMA Foundation
Phase 2CCC
cc-5013
PETHEMA Foundation
Phase 2CCC
DARATUMUMAB
PETHEMA Foundation
Phase 2CCC

View all 11 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →